Get the latest tech news
Promising new epilepsy drug delivers 80% reduction in seizures | Adults with drug-resistant focal onset seizures are the target of experimental epilepsy drug RAP-219
A new drug candidate has shown impressive results in a mid-stage clinical trial for drug-resistant epilepsy, raising hopes for patients who continue to suffer seizures despite being on multiple medications.
A new drug candidate has shown impressive results in a mid-stage clinical trial for drug-resistant epilepsy, raising hopes for patients who continue to suffer seizures despite being on multiple medications. Rapport Therapeutics has announced that its experimental compound RAP-219 reduced seizures by an average of 77.8% in a Phase 2a study, with almost a quarter of participants remaining seizure-free over the two-month treatment period. All participants were fitted with an implanted responsive neurostimulation (RNS) device, which continuously monitored brain activity and allowed researchers to measure clinical seizures and an objective electrographic marker called “long episodes.”
Or read this on r/tech
